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A B S T R A C T
Purpose
Retrospective studies indicate that expression of excision repair cross complementing group 1
(ERCC1) protein is associated with platinum resistance and survival in non–small-cell lung cancer
(NSCLC). We conducted the ﬁrst randomized trial, to our knowledge, to evaluate ERCC1 prospectively
and to assess the superiority of nonplatinum therapy over platinum doublet therapy for ERCC1-positive
NSCLC as well as noninferiority for ERCC1-negative NSCLC.
Patients and Methods
This trial had amarker-by-treatment interaction phase III design, with ERCC1 (8F1 antibody) status as
a randomization stratiﬁcation factor. Chemonaı¨ve patients with NSCLC (stage IIIB and IV) were
eligible. Patients with squamous histology were randomly assigned to cisplatin and gemcitabine or
paclitaxel and gemcitabine; nonsquamous patients received cisplatin and pemetrexed or paclitaxel
and pemetrexed. Primary end point was overall survival (OS).We also evaluated an antibody speciﬁc
for XPF (clone 3F2). The target hazard ratio (HR) for patients with ERCC1-positive NSCLC
was # 0.78.
Results
Of patients, 648 were recruited (177 squamous, 471 nonsquamous). ERCC1-positive rates were 54.5%
and 76.7% in nonsquamous and squamous patients, respectively, and the corresponding XPF-positive
rates were 70.5% and 68.5%. Accrual stopped early in 2012 for squamous patients because OS for
nonplatinum therapywas inferior to platinum therapy (medianOS, 7.6months [paclitaxel andgemcitabine]v
10.7 months [cisplatin and gemcitabine]; HR, 1.46; P = .02). Accrual for nonsquamous patients
halted in 2013. Median OS was 8.0 (paclitaxel and pemetrexed) versus 9.6 (cisplatin and
pemetrexed) months for ERCC1-positive patients (HR, 1.11; 95% CI, 0.85 to 1.44), and 10.3
(paclitaxel and pemetrexed) versus 11.6 (cisplatin and pemetrexed) months for ERCC1-negative
patients (HR, 0.99; 95% CI, 0.73 to 1.33; interaction P = .64). OS HR was 1.09 (95% CI, 0.83 to
1.44) for XPF-positive patients, and 1.39 (95% CI, 0.90 to 2.15) for XPF-negative patients (in-
teraction P = .35). Neither ERCC1 nor XPF were prognostic: among nonsquamous patients, OS
HRs for positive versus negative were ERCC1, 1.11 (P = .32), and XPF, 1.08 (P = .55).
Conclusion
Superior outcomes were observed for patients with squamous histology who received platinum
therapy compared with nonplatinum chemotherapy; however, selecting chemotherapy by using
commercially available ERCC1 or XPF antibodies did not confer any extra survival beneﬁt.
J Clin Oncol 35:402-411. © 2016 by American Society of Clinical Oncology
INTRODUCTION
Little progress has been made in managing wild-
type non–small-cell lung (NSCLC) cancer in the
last decade compared with advances that have
been made in treating the small subpopulations of
epidermal growth factor receptor (EGFR)–positive
and anaplastic lymphoma kinase–positive tumors
with tyrosine kinase inhibitor therapy. Most pa-
tients with advanced NSCLC are treated with a
platinum doublet. An effective predictive bio-
marker is required to direct treatment to improve
outcomes.
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One of the most promising biomarkers is excision repair cross
complementing group 1 (ERCC1) protein, which is involved in the
repair of cytotoxic platinum DNA adducts.1-4 These adducts es-
tablish covalent cross-linking within and between DNA strands,
which inhibits DNA replication and leads to cell death. ERCC1
binds to XPF protein, forming a heterodimer complex that cleaves
DNA structures near the platinum adduct and allows for removal
of the cytotoxic DNA lesion.
ERCC1 has been examined as a prognostic or predictive marker
in several cancers that are treated with platinum chemotherapy. In-
creased ERCC1 expression is thought to be associated with platinum
resistance in retrospective NSCLC studies.5 In a meta-analysis of these
studies of patients with advanced NSCLC who were treated with
platinum therapy, mortality was higher in ERCC1-positive patients
than in those with low expression (overall survival [OS] hazard ratio
[HR], 1.48).6 Recent studies similarly conclude that ERCC1 is
prognostic,7 but others do not.8,9 ERCC1 gene polymorphisms
have also been investigated, but results are inconsistent for NSCLC,
again often on the basis of retrospective studies.10-12
Analyses of stored samples from 761 resected patients with
early-stage NSCLC (International Adjuvant Lung Cancer Trial
[IALT]) suggested that platinum chemotherapy versus no che-
motherapy had a different effect among ERCC1-negative patients
(HR, 0.65) than among ERCC1-positive patients (HR, 1.14; P= .006).13
Consequently, several centers use ERCC1 to customize treatment.
Review articles and the Centre for Comparative Effectiveness Research
in Cancer Genomics identiﬁed ERCC1 as a top research priority
because its use lacked high-quality evidence, with current evidence
on the basis of retrospective studies.14,15
We conducted the ﬁrst—to our knowledge—large, phase III
study to prospectively evaluate ERCC1 in any tumor type as
a predictive and prognostic biomarker.
PATIENTS AND METHODS
Study Design and Participants
The ERCC1 trial (ET) was a phase III randomized trial conducted
across 85 UK hospitals to determine whether nonplatinum therapy is
superior to platinum therapy for patients with NSCLC with ERCC1-
positive tumors, but noninferior for patients with ERCC1-negative
tumors. Inclusion criteria were age $ 18 years with histologic con-
ﬁrmation of advanced NSCLC (stage IIIb or IV), no prior chemo-
therapy, one or more measurable lesions (Response Evaluation Criteria
in Solid Tumors v1.1 [RECIST v1.1]), Eastern Cooperative Oncology
Group performance status of 0 to 1, and stable brain metastases (if present).
Centers that routinely performed EGFR testing did not refer EGFR-positive
patients to ET.
The trial had ethics approval and was conducted according to the
Declaration of Helsinki.
Random Assignment
Registered patients had their tumor sample sent for central ERCC1
testing and were only randomly assigned after the result was known. Random
assignment was performed by telephoning the Trials Center, where a com-
puter program allocated patients by using minimization, stratiﬁed by ERCC1
status (positive v negative), disease stage (IIIb v IV), smoking history (never,
former, or current), and hospital. This was done separately for nonsquamous
(includes adenocarcinoma, large cell, and not otherwise speciﬁed) and
squamous patients because of the different treatments.
Procedures
Small biopsied specimens that were obtained mainly from primary
tumors (formalin ﬁxed and parafﬁn embedded) were sent to University
College London Advanced Diagnostics—a Clinical Pathology Accredited
and Host Laboratory for the UK National External Quality Assessment
Service—for centralized ERCC1 testing (immunohistochemistry).
We used an approved 8F1 ERCC1 antibody (Neomarkers, Fisher
Scientiﬁc, Loughborough, UK) and clone Ab-2 (8F1; 1/300 dilution) and
fully automated Leica Biosystems Bond III. Two expert pathologists (M.F.
and A.C.) scored each sample blindly, classifying ERCC1 positive as
moderate expression in $ 50% of tumor cells, or strong expression in
$ 10% of tumor cells.13 The quality control validation process involved
testing each new antibody batch against established controls from both
normal tonsil and tumors with known ERCC1 expression to ensure re-
producibility and accurate interpretation.
From April 2013, after new information about the ERCC1-8F1
antibody,16 the Independent Data Monitoring Committee (IDMC) and
investigators added anti–XPF clone 3F2/3 (AbCam, Cambridge, UK),
which is speciﬁc for the XPF-ERCC1 protein complex,17 because XPF
is also involved in the repair of the cytotoxic platinumDNA adduct. Thirty-
four patient samples were measured prospectively and 614 retrospectively.
Random assignment was still based on the ERCC1-8F1 antibody. XPF was
scored by using QuickScore (familiar to many pathologists)18 as the sum of
staining intensity (score 1 to 3) and proportion of cells stained (score 1 to 5),
with a score of$ 6 signifying positive staining for the ERCC1-XPF complex.
Doublet chemotherapy was administered once every three weeks, up
to 6 cycles (using standard regimens). Squamous patients were randomly
assigned to cisplatin 75 mg/m2 day 1 plus gemcitabine 1,250 mg/m2 days 1
and 8, or to paclitaxel 175 mg/m2 day 1 plus gemcitabine. Nonsquamous
patients were randomly assigned to cisplatin plus pemetrexed 500mg/m2
day 1, or to paclitaxel plus pemetrexed. Paclitaxel was used because it is more
cost effective than docetaxel, with little association between ERCC1 expression
and sensitivities to paclitaxel (regimens used from prior phase II studies).19
Clinical examinations, biochemistry, and chest x-rays were per-
formed at baseline, before each chemotherapy cycle, and monthly until
1 year from the start of the ﬁrst chemotherapy cycle, then every 2 months
thereafter. Chest and abdomen computed tomography scans were per-
formed after cycles 2, 4, and 6, or when clinically indicated thereafter.
Statistical Considerations
The primary end point was OS. Secondary end points were progression-
free survival (PFS), tumor response, adverse events, chemotherapy adherence,
and health-related quality of life (European Organisation for Research and
Treatment of Cancer Quality of Life Questionnaire C30 and LC13).20
For ERCC1-negative patients, the expected median OS was 9 months
(United Kingdom audit data), with a noninferiority margin of 1.5 months
(HR should not be $ 1.2), which required 669 deaths (80% power, 5%
one-sided statistical signiﬁcance). For ERCC1-positive patients, we aimed
to increase OS from 9 months (platinum) to 11.5 months (nonplatinum),
a minimum clinically important beneﬁt (target HR# 0.78, which required
511 deaths; 80% power, 5% two-sided statistical signiﬁcance. Total target
was 1,272 patients.
Analyses were by intention-to-treat. Time-to-event end points were
analyzed by using the log rank test and Cox proportional hazards re-
gression model, measured from the random assignment date. For OS,
surviving patients were censored at the date last seen alive, and for PFS,
an event was RECIST progression or death from any cause and those
without an event were censored when last seen alive. ERCC1 and XPF
were each examined as predictive—that is, whether the marker status
inﬂuenced the OS or PFS HR for nonplatinum versus platinum, using
an interaction test—and prognostic—that is, whether marker status is
correlated with OS or PFS, using multivariable Cox proportional hazards
regression. Toxicities were based on the maximum National Cancer In-
stitute Common Terminology Criteria for Adverse Events toxicity grade for
each patient and event. Quality of life was analyzed by using mixed modeling
for repeated measures.
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Early Stopping
Since September 2012, we excluded squamous patients after the
IDMC observed that OS and PFS were signiﬁcantly better with plat-
inum therapy. Squamous histology patients who were still taking
nonplatinum treatment and their clinicians were informed and rec-
ommended to switch to platinum therapy, unless there was beneﬁt. In
July 2013, the IDMC recommended closing the trial for two reasons:
reanalysis of the IALT16 indicated that the 8F1-ERCC1 antibody was
questionable, with updated results showing it to not be predictive, and
our observed ET data were consistent with these ﬁndings (OS HR, 1.08
among ERCC1-positive patients, and the 0.78 target was unlikely to be
achieved if ET continued).
RESULTS
Of patients, 648 were randomly assigned between October 2009
and July 2013 (Fig 1). Baseline characteristics were similar between
groups (Table 1).
(n = 1)
Squamous Nonsquamous
Random assignment Random assignment
(n = 87)
Cisplatin/Gemcitabine
(n = 90)
Paclitaxel/Gemcitabine
(n = 235)
Cisplatin/Pemetrexed
(n = 236)
Paclitaxel/Pemetrexed
Had prior 
radiotherapy
(n = 1)
Had primary rectal 
cancer; creatinine
too low
(n = 2)
(n = 2)
Incorrect histology 
(allocated to incorrect 
chemotherapy;
n = 1)
Incorrect histology 
(allocated to incorrect 
chemotherapy;
n = 1)
(n = 84) (n = 89)
Withdrew consent 
before starting trial
Had primary
rectal cancer
(n =1)
Had myocardial 
infarction before 
starting chemotherapy 
(n = 1)
(n = 234)
EGFR positive so 
had Iressa instead 
of chemotherapy
(n =1)
No. patients ineligible:
(n = 230)
Included in 
intention-to-treat analyses 
Other reasons 
for exclusion
Patients with 
histologically confirmed 
stage IIIb or IV NSCLC
(N = 648)
Initial Registration
Sample sent for central 
ERCC1 testing
ERCC1 positive
Report to trials center*
ERCC1 negative
Fig 1. CONSORTdiagram.When the urgent safetymeasurewas implemented (September 2012), four patientswith squamous histology switched frompaclitaxel to cisplatin
and carboplatin, 13 stopped trial treatment, two died shortly after stopping paclitaxel and gemcitabine, and one continued with platinum therapy. All other squamous patients
had already ﬁnished their chemotherapy or had diedpreviously. *Minimizationwas used to randomly assign patients, but only after excision repair cross complementing group 1
(ERCC1) status and histology were known. Squamous patients were then randomly assigned between each treatment arm using stratiﬁcation factors ERCC1, smoking, stage,
and center. This process ensured balance between the arms for each of these factors, such that they do not differ between the groups (and hence would not act as
confounders). The same was done separately for nonsquamous patients. EGFR, epidermal growth factor receptor; NSCLC, non–small-cell lung cancer.
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ERCC1 results were available for 95% of patients within 3 days
after the central laboratory received samples (Appendix Table A1,
online only). The ERCC1-positive rate for all patients was 60.6%
(386 of 637 patients) or 69.9% (332 of 475 patients) using the 8F1
or anti-XPF antibodies, respectively. Corresponding positive rates
were 54.5% (253 of 464 patients) and 70.5% (234 of 332 patients)
for nonsquamous histology, and 76.7% (133 of 173 patients) and
68.5% (98 of 143 patients) for squamous histology. Appendix Table
A2 (online only) lists the concordance between ERCC1 and XPF.
Chemotherapy Adherence
Thirty two patients did not start trial chemotherapy after
random assignment (Appendix Table A3, online only). Among
those who started treatment, the percentage of patients who
completed at least four cycles was 67.9% (platinum) versus 60.2%
(nonplatinum) for those with nonsquamous histology (P = .11),
and 58.7 versus 54.2% (P = .64) for those with squamous histology.
Appendix Table A4 (online only) lists reasons for nonadherence.
There was no material difference in the number of cycles
(P = .09, nonsquamous; and P = .25, squamous histology). The
proportions with dose reductions were broadly similar, but more
patients seemed to have dose delays in the platinum therapy groups
(both histologies). Median drug dose administered was as ex-
pected, without differences between groups (Appendix Table A5,
online only). Additional treatments after trial chemotherapy are
listed in Appendix Table A6 (online only).
ERCC1 and XPF as Predictive Biomarkers
Among evaluable patients with squamous histology, the
partial or complete tumor response rate was 51.6% (platinum)
versus 26.5% (nonplatinum; P= .004), and was similar for ERCC1-
positive patients (50.0 v 27.4%) and ERCC1-negative patients
(57.1 v 23.5%; Appendix Table A7, online only). Among those with
nonsquamous histology, the response rate was higher for platinum
therapy versus nonplatinum therapy (48.4 v 33.0%; P = .04) in
patients whowere ERCC1 positive and similar in patients whowere
ERCC1 negatives (32.9 v 39.0%; P = .51). Appendix Table A8
(online only) lists odds ratios for ERCC1 as a predictive marker of
response, with no evidence of an association among squamous
histology patients (interaction P = .58). Although the interaction
P value was of borderline statistical signiﬁcance for nonsquamous
subtypes (P = .04), results for ERCC1-positive patients contrasted
with our hypothesis.
Median follow-up was 30 months; there were 563 deaths (511
from lung cancer) and 594 PFS events. OS and PFS were similar
between nonsquamous histology patients who received platinum
therapy and nonplatinum therapy (Fig 2). For squamous histology
patients, OS and PFS were signiﬁcantly better with platinum
therapy compared with nonplatinum treatment (Fig 2).
Baseline characteristics were similar between ERCC1-positive
patients and ERCC1-negative patients (Appendix Table A9, online
only). Appendix Fig A1 (online only) shows Kaplan-Meier curves
comparing platinum treatment and nonplatinum treatment
according to ERCC1 status (8F1 antibody) in all patients (HRs are
for nonplatinum v platinum therapy). There was no evidence of
superiority for nonplatinum therapy (OS or PFS) among ERCC1-
positive patients; however, because the effects differed between
squamous and nonsquamous subtypes, results are presented sep-
arately hereafter. Figure 3 and Appendix Fig A2 (online only) show
no evidence for a treatment-by-ERCC1 interaction for either OS
(P = .64 nonsquamous; P = .51 squamous histology) or PFS (P = .84
Table 1. Baseline Characteristics of 637 Patients Included in the Analyses
Characteristic
Squamous Histology Nonsquamous Histology
Cisplatin and Gemcitabine
(n = 84)
Paclitaxel and Gemcitabine
(n = 89)
Cisplatin and Pemetrexed
(n = 230)
Paclitaxel and Pemetrexed
(n = 234)
Median age, years (range) 67 (48-76) 66 (37-84) 63 (39-79) 64 (35-79)
Sex
Male 79 (66) 71 (63) 58 (133) 56 (131)
Female 21 (18) 29 (26) 42 (97) 44 (103)
ECOG PS
0 44 (37) 34 (30) 44 (101) 46 (107)
1 56 (47) 66 (59) 56 (129) 54 (127)
Stage
IIIb 29 (24) 34 (30) 20 (45) 21 (49)
IV 71 (60) 66 (59) 80 (185) 79 (185)
Smoking
Never 4 (3) 4 (4) 9 (22) 10 (23)
Former 40 (34) 45 (40) 43 (98) 42 (98)
Current 56 (47) 51 (45) 48 (110) 48 (113)
ERCC1
Negative 23 (19) 24 (21) 46 (105) 45 (106)
Positive 77 (65) 76 (68) 54 (125) 55 (128)
XPF
Negative 24 (21) 27 (24) 22 (51) 20 (47)
Positive 55 (45) 60 (53) 52 (120) 49 (114)
Unavailable* 21 (18) 13 (12) 26 (59) 31 (73)
NOTE. Data are given as % (No.) unless otherwise noted.
Abbreviations: ECOG, Eastern Cooperative Oncology Group; ERCC1, excision repair cross complementing group 1; PS, performance score.
*Insufﬁcient sample.
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nonsquamous; P = .12 squamous). Among patients with non-
squamous histology, although the observed OS HR of 0.99 was
within the noninferiority limit of 1.20 in ERCC1-negative patients,
the HR in positive patients (1.11) was not lower than the target effect
of 0.78, and the median OS was higher with platinum therapy
(9.6 months v 8.0 months; Fig 3). Among patients with squamous
histology, all HRs exceeded 1.0 regardless of ERCC1 status (Appendix
Fig A2).
Results were similar after excluding 32 patients who did not start
trial chemotherapy and censoring four patients with squamous
histology when they switched from nonplatinum therapy to
platinum therapy after the IDMC recommendation, or after
excluding patients randomly assigned to platinum therapy who later
received a taxane (docetaxel) as well as those randomly assigned
to paclitaxel who later received platinum therapy (Appendix
Table A10, online only).
We conducted similar analyses for XPF. Baseline character-
istics were similar between XPF-negative patients and XPF-positive
patients (Appendix Table A11, online only). Kaplan-Meier curves
are shown in Fig 4 (nonsquamous) and Appendix Fig A3 (online
only; squamous). OS seemed to be better for platinum treatment
than for nonplatinum treatment among patients with non-
squamous histology who were XPF negative, though not sta-
tistically signiﬁcant at the 0.05 level (median 11.6 months v
8.9 months; HR, 1.39; P = 1.14), but given the OS HR (1.09)
among XPF-positive patients, interaction P value was .35. This was
in contrast to an apparent survival beneﬁt for platinum therapy in
squamous histology patients who were XPF positive (OS HR, 1.65;
P = .02; PFS HR, 1.88; P = .003), with no effect among XPF-
negative patients (OS HR, 1.06; P = .86; PFS HR, 1.30; P = .39;
interaction P = .21 for OS). Using higher scores to categorize
patients as XPF positive produced similar results (Appendix Table
A12, online only).
Analyses that examined the predictive effects of ERCC1 or
XPF according to sex, disease stage, and smoking did not show any
subgroup effects (Appendix Table A13, online only).
We combined ERCC1 and XPF and still found no evidence
that they were predictive. OS HR among patients with non-
squamous subtypes who were positive for both markers was 1.09
(95% CI, 0.78 to 1.51) compared with 1.16 (95% CI, 0.67 to 1.99)
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Fig 2. Overall survival (OS) and progression-free survival (PFS) curves according to histology. Unadjusted hazard ratios (HRs) are shown (HRs are for nonplatinum v
platinum). HR (95% CI) adjusted for the random assignment stratiﬁcation factors are 1.17 (0.92 to 1.47). 1.22 (0.98 to 1.54), 1.38 (0.89 to 2.13), and 1.44 (0.93 to 2.23) for
nonsquamous OS and PFS and squamous OS and PFS, respectively.
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for patients who were negative for both markers, that is, not
materially different. The corresponding HRs for squamous his-
tology were 1.56 (95% CI, 1.00 to 2.43) and 1.82 (95% CI, 0.64 to
5.17), respectively.
ERCC1 and XPF As Prognostic Biomarkers
Unlike many retrospective studies,6 neither ERCC1 nor XPF
were prognostic markers for OS or PFS (Table 2 and Appendix
Fig A4, online only; HRs are for marker positive v negative). All
but one of the associations indicated that ERCC1-positive pa-
tients or XPF-positive patients had outcomes that were similar
to patients who were negative, overall or within each treatment
group (the association [PFS HR, 1.86 in squamous histology]
had a P value of .03, possibly as a result of multiple testing and
only 84 patients). Similar conclusions were made after com-
bining ERCC1 and XPF: the adjusted OS HR comparing pa-
tients who were positive for both markers with those who
were negative for both was 1.08 (95% CI, 0.79 to 1.44) for
nonsquamous histology, and 0.87 (95% CI, 0.51 to 1.47) for squa-
mous histology.
Adverse Events and Quality of Life
The proportion of patients who experienced any grade 3 to 5
adverse events was similar between platinum and nonplatinum
groups: 66.7% versus 70.8% (squamous, P = .56), and 69.1%
versus 72.2% (nonsquamous, P = .46; Appendix Tables A14 and
A15, online only). Health-related quality of life was also broadly
similar (Appendix Table A16, online only).
DISCUSSION
ET is the ﬁrst randomized phase III study in advanced NSCLC
speciﬁcally designed to evaluate prospective testing of ERCC1 as
a predictive biomarker. Neither tumor ERCC1 nor XPF protein
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Fig 3. Overall survival (OS) and progression-free survival (PFS) curves by excision repair cross complementing group 1 (ERCC1) status (8F1 antibody), among non-
squamous histology. Unadjusted hazard ratios (HRs) are shown (HRs are for nonplatinum v platinum). HR (95%CI) adjusted for the random assignment stratiﬁcation factors
are 1.20 (0.81 to 1.78), 1.41 (0.96 to 2.08), 1.11 (0.79 to 1.56), and 1.32 (0.94 to 1.85) for ERCC1-negative patients OS and PFS, and ERCC1-positive patients OS and PFS,
respectively. Test for interaction (between ERCC1 and treatment) was P = .64 (OS) and P = .84 (PFS). Two-tailed P = .94 (OS in ERCC1-negative patients) applies to the null
hypothesis of HR, 1.0. One-tailed P value for the null hypothesis of HR$ 1.20 versus alternative HR, 1.20 (ie, the prespeciﬁed noninferiority margin) is 0.09 where P, .05
is evidence for noninferiority.
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expression using commercially available antibodies predicted
outcomes for platinum therapy or nonplatinum chemotherapy.
More patients with squamous histology had high ERCC1
expression (77%) than did nonsquamous patients (55%), which is
similar to other reports.13,21 Despite this higher rate, which was
thought to be associated with platinum resistance, platinum
therapy was signiﬁcantly better (response rate, PFS, and OS) than
nonplatinum therapy in patients with squamous histology. Results
for squamous histology patients indicated that OS (10.7 months v
7.6 months), PFS (8.0 months v 5.0 months), and response rate
(51.6% v 26.5%) after platinum therapy were all better than ex-
pected, even though the patient group seemed similar to those
reported in practice and studies (Appendix Table A17, online
only).22,23 Squamous NSCLC might have different DNA repair
proﬁles for platinum and nonplatinum therapy compared with
nonsquamous subtypes, thus warranting further investigation. To
our knowledge, this is the ﬁrst time any randomized trial has
shown superior outcomes among squamous NSCLC treated with
platinum versus nonplatinum therapy, and these patients should
continue to have this.
For nonsquamous tumors, although nonplatinum therapy
was noninferior to platinum therapy among ERCC1-negative patients
(OS HR, 0.99), we could not demonstrate that nonplatinum was
superior among ERCC1-positive patients (OS HR, 1.11; superiority
P = 0.60; target HR, 0.78).
We also did not ﬁnd a correlation between ERCC1 and OS
and PFS, unlike that reported in retrospective studies. OS among
nonsquamous histology patients with ERCC1-positive tumors
was similar to those who were negative (median, 9.6 months v
11.6 months; HR, 1.05).
Our study strengths were as follows: evaluation of both the
8F1-ERCC1 and 3F2-XPF antibodies assessed centrally by two
consultant pathologists which increased the accuracy and re-
liability of the analysis; the ability to examine each marker as
predictive or prognostic; and ERCC1 was measured pro-
spectively in all patients in real time, with ERCC1 stratiﬁcation
incorporated into the randomization to ensure balance be-
tween treatment groups.
Only three previous trials have measured ERCC1 pro-
spectively, but all used it to direct treatment and so they could not
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Fig 4. Overall survival (OS) and progression-free survival (PFS) curves by XPF status, among nonsquamous histology. Test for interaction (between excision repair cross
complementing group 1 [ERCC1] and treatment) was P= .35 (OS) and P= .40 (PFS). Two-tailed P= .14 (OS in XPF-negative patients) applies to the null hypothesis of hazard
ratio (HR), 1.0. One-tailed P value for the null hypothesis of HR $ 1.20 versus alternative HR , 1.20 (ie, the prespeciﬁed noninferiority margin) is 0.74 where P , .05 is
evidence for noninferiority (HRs are for nonplatinum v platinum).
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allow for any prognostic interaction effect of ERCC1,24-26 and
there was no comparator group without directed treatment. Two
trials considered ERCC1 to inﬂuence response rates,24,25 whereas
the other found no effect.26 ET has the only design that is able to
compare platinum therapy with nonplatinum therapy in each
ERCC1-positive and ERCC1-negative group, that is, a marker-by-
treatment interaction design.27
We encountered some challenges: introduction of routine
local EGFR mutation testing at hospitals competed with ET for
tissue blocks of eligible patients; 25% of samples received were
small and were just enough for ERCC1 testing; and 70 patients
were not randomly assigned because of insufﬁcient sample. ET
was designed and set up in 2008 when the 8F1-assay for ERCC1
was in common use, but after accumulating evidence, the re-
liability of this assay was questioned. It would be difﬁcult to
switch to another biomarker in the prospective randomization
process, which is an important potential problem for future
biomarker-driven trials.
Several reasons might explain our ﬁndings. First, lack of
speciﬁcity of ERCC1 immunohistochemistry testing, despite
using the recommended 8F1 antibody when our trial was
launched.17,28-31 Second, although the 55% observed ERCC1-
positive rate for nonsquamous histology patients in our trial is
within the range reported from other studies (31% to 65%), some
variability may be a result of different ﬁxation methods, newer
antibody batches, and different thresholds for classifying posi-
tivity.6 Of interest, within the IALT, the rate was 44% in 2006 but
77% in the subsequent reanalyses of the same samples using
a different antibody batch.13,16 During ET, the ERCC1-positive rate
did not change noticeably over time, despite using different an-
tibody batches.
In the 2006 IALTreport,13 the OSHR for chemotherapy versus
no therapy was 0.65 among ERCC1-negative patients, but 1.14 in
ERCC1-positive patients, with a strong treatment-by-ERCC1 in-
teraction (P = .009). However, reanalyses of the same samples using
a different batch produced corresponding HRs of 0.81 and 0.96,
respectively, with no evidence that ERCC1 was predictive (in-
teraction P = .53).16 Analyses of two other trials with the later batch
showed similar inconsistent results.16 The authors concluded that
only one of four ERCC1 protein isoforms (202) had full capacity
for nucleotide excision repair and cisplatin resistance, but none of
the 16 commercially available antibodies distinguishes between
them.16,32 Processing issues associated with ERCC1 testing requires
a validated standard procedure to be developed for future
studies.6,33
After reports on the speciﬁcity of the 8F1 antibody to detect
functional ERCC1 during ET (ﬁrst raised by Bhagwat et al,17 who
found it cross-reacted with an unrelated protein), we revised our
protocol to also examine the obligate XPF partner protein ex-
pression by using an anti-XPF antibody.17 Repair of the cytotoxic
platinum DNA adducts involve the ERCC1-XPF heterodimer
complex.34,35 XPF expression using 3F2 anti-XPF antibody could
be a better predictive biomarker than 8F1-ERCC1 for platinum
therapy,17,36 and targeting XPF-ERCC1 by RNA interference in-
creases cisplatin efﬁcacy.37 Several studies suggest a role of XPF in
platinum resistance.37,38 In ET, we observed that patients with
nonsquamous histology who were XPF negative derived some
beneﬁt from platinum therapy (HR, 1.39; P = .14), but this is
inconclusive and there was little association in XPF-positive pa-
tients (HR, 1.09; P = .52).
Because the active ERCC1 202 isoform is associated with
XPF to form the only functional heterodimer,32 such that
a coexpression between ERCC1 and XPF dimers might have
a stronger predictive value than either marker alone, we an-
alyzed our data for patients who were positive for both ERCC1
and XPF (compared with those who were negative for both). We
Table 2. ERCC1 or XPF As a Prognostic Marker: Association With OS or PFS
OS PFS
No. of Patients (events) HR (95% CI) P No. of Patients (events) HR (95% CI) P
Nonsquamous histology
ERCC1
Cisplatin and pemetrexed 230 (198) 1.05 (0.80 to 1.40) .72 230 (215) 1.12 (0.85 to 1.46) .43
Paclitaxel and pemetrexed 234 (201) 1.14 (0.86 to 1.51) .36 234 (212) 1.14 (0.86 to 1.49) .36
Combined* 464 (399) 1.11 (0.91 to 1.35) .32 464 (427) 1.13 (0.93 to 1.37) .22
XPF
Cisplatin and pemetrexed 171 (147) 1.20 (0.83 to 1.72) .33 171 (160) 1.22 (0.87 to 1.73) .25
Paclitaxel and pemetrexed 161 (138) 0.96 (0.66 to 1.39) .82 161 (146) 1.00 (0.69 to 1.44) .99
Combined* 332 (285) 1.08 (0.83 to 1.40) .55 332 (306) 1.10 (0.86 to 1.42) .44
Squamous histology
ERCC1
Cisplatin and gemcitabine† 84 (78) 1.49 (0.85 to 2.60) .16 84 (80) 1.86 (1.06 to 3.26) .03
Paclitaxel and gemcitabine† 89 (86) 0.94 (0.56 to 1.56) .80 89 (87) 0.76 (0.45 to 1.28) .30
Combined*† 173 (164) 1.12 (0.77 to 1.63) .55 173 (167) 1.12 (0.77 to 1.64) .52
XPF
Cisplatin and gemcitabine 66 (62) 0.72 (0.42 to 1.23) .23 66 (64) 0.73 (0.43 to 1.25) .26
Paclitaxel and gemcitabine 77 (74) 1.11 (0.68 to 1.83) .67 77 (75) 1.18 (0.72 to 1.93) .52
Combined* 143 (136) 0.91 (0.63 to 1.31) .61 143 (139) 0.92 (0.64 to 1.33) .67
NOTE. HRs are for positive versus negative ERCC1 or XPF status (Appendix Fig A4).
Abbreviations: ERCC1, excision repair cross complementing group 1; HR, hazard ratio; OS, overall survival; PFS, progression-free survival.
*HRs are adjusted for treatment group.
†HRs are adjusted for stage and smoking status because, from Appendix Table A8, they were not far from statistical signiﬁcance.
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again found no evidence for them to be either prognostic or
predictive.
Although the IDMC stopped ET early, it was not un-
derpowered. The primary objective was to show that non-
platinum therapy is more effective than platinum therapy
among ERCC1-positive patients. Conditional power is the
chance of obtaining the target OS HR of # 0.78 if the trial had
continued to the planned end (target 511 deaths), given the
observed number of deaths and observed HR. It would have
been futile to continue because conditional power was small:, 0.01%
among all patients (352 deaths), and 7% among nonsquamous
subtypes (225 deaths).
In conclusion, patients with advanced squamous NSCLC
who were treated with nonplatinum chemotherapy had sig-
niﬁcantly worse outcomes than did those who were treated with
platinum chemotherapy. Prospectively selecting the type of
chemotherapy using the 8F1 or XPF antibody for ERCC1 did
not predict OS or PFS for either histologic subtype. Further-
more, ERCC1 and XPF were not prognostic markers for ad-
vanced NCSLC. Neither ERCC1 nor XPF, using current
commercial tests, should be used in routine practice without
further investigation. Future studies could focus on developing
assays that target the functional ERCC1 202 protein, which may
be associated with cisplatin resistance.
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Fig A1. Overall survival (OS) and progression-free survival (PFS) curves according to excision repair cross complementing group 1 (ERCC1) status (8F1 antibody),
nonsquamous and squamous histologies combined. Unadjusted hazard ratios (HRs) are shown (for nonplatinum v platinum). HR (95%CI) adjusted for random assignment
stratitiﬁcation factors are 1.28 (0.89 to 1.83), 1.53 (1.07 to 2.18), 1.22 (0.94 to 1.59), and 1.30 (1.00 to 1.69) for ERCC1-negative patients OS and PFS and ERCC1-positive
patients OS and PFS, respectively. Two-tailed P = .52 (OS in ERCC1-negative patients) applies to the null hypothesis of HR, 1.0. One-tailed P value for the null hypothesis of
HR $ 1.20 versus alternative HR , 1.20 (ie, the prespeciﬁed noninferiority margin) is 0.25.
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Fig A2. Overall survival (OS) and progression-free survival (PFS) curves by excision repair cross complementing group 1 (ERCC1) status (8F1 antibody), among squamous
histology. Unadjusted hazard ratios (HRs) are shown (for nonplatinum v platinum). HR (95% CI) adjusted for random assignment stratitiﬁcation factors are 2.20 (1.08 to
4.48), 5.21 (2.23 to 12.18), 1.61 (0.94 to 2.76), and 1.48 (0.87 to 2.53) for ERCC1-negative patients OS and PFS and ERCC1-positive patients OS and PFS, respectively. Test
for interaction (between ERCC1 and treatment) was P = .51 (OS) and P = .12 (PFS). Two-tailed P = .14 (OS in ERCC1-negative patients) applies to the null hypothesis of HR,
1.0. One-tailed P value for the null hypothesis of HR $ 1.20 versus alternative HR , 1.20 (ie, the prespeciﬁed noninferiority margin) is 0.76 where P , .05 is evidence for
noninferiority.
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Fig A3. Overall survival (OS) and progression-free survival (PFS) curves by XPF status, among squamous histology. Test for interaction (between excision repair cross
complementing group 1 [ERCC1] and treatment) was P = .21 (OS) and P = .24 (PFS). Two-tailed P = .86 (OS in XPF-negative patientss) applies to the null hypothesis of
hazard ratio (HR), 1.0. One-tailed P value for the null hypothesis of HR$ 1.20 versus alternative HR, 1.20 (ie, the prespeciﬁed noninferiority margin) is 0.34 where P, .05
is evidence for noninferiority. HRs for nonplatinum versus platinum therapy.
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Fig A4. Excision repair cross complementing group 1 (ERCC1) and XPF as prognostic markers for overall survival: Kaplan-Meier curves of marker positive and negative
patients, according to histology and whether they received platinum or nonplatinum therapy. Hazard ratios are listed in Table 2.
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Table A1. ERCC1 Testing
Working Days, No. Patients, No. (%)
1 261 (44.2)
2 227 (38.4)
3 72 (12.2)
4 19 (3.2)
5 4 (0.7)
6 2 (0.3)
7 3 (0.5)
8 2 (0.3)
12 1 (0.2)*
NOTE. Number of working days from when the tissue block was received by
the central laboratory until the ERCC1 result was reported to the trials center
(n = 591; dates were missing for 57 patients). Median time taken was 2 days.
Abbreviation: ERCC1, excision repair cross complementing group 1.
*An incorrect block was sent initially (endometrial tissue), so a second (lung)
sample had to be requested, hence the 12 days
Table A2. Concordance Between the 8F1 ERCC1 Antibody and XPF Clone XPF
3F2/3 Antibody Among 637 Patients Analyzed
XPF
ERCC1
Negative Positive
Squamous and nonsquamous patients
Negative 85 (33.9) 58 (15.0)
Positive 82 (32.7) 250 (64.8)
Insufﬁcient sample 84 (33.5) 78 (20.2)
Nonsquamous patients
Negative 68 (32.2) 30 (11.9)
Positive 72 (34.1) 162 (64.0)
Insufﬁcient sample 71 (33.7) 61 (24.1)
Squamous patients
Negative 17 (42.5) 28 (21.0)
Positive 10 (25.0) 88 (66.2)
Insufﬁcient sample 13 (32.5) 17 (12.8)
NOTE. Data are given as No. (%).
Abbreviation: ERCC1, excision repair cross complementing group 1.
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Table A3. Adherence to Trial Chemotherapy
Chemotherapy
Squamous Histology Nonsquamous Histology
Cisplatin and Gemcitabine
(n = 84)
Paclitaxel and Gemcitabine
(n = 89)
Cisplatin and Pemetrexed
(n = 230)
Paclitaxel and Pemetrexed
(n = 234)
No. of completed cycles
0 (did not start) 4.8 (4) 6.7 (6) 4.8 (11) 4.7 (11)
1 14.3 (12) 11.2 (10) 10.9 (25) 8.5 (20)
2 9.5 (8) 22.5 (20) 10.4 (24) 20.5 (48)
3 15.5 (13) 9.0 (8) 9.1 (21) 8.5 (20)
4 27.4 (23) 23.6 (21) 20.4 (47) 17.5 (41)
5 7.1 (6) 5.6 (5) 8.7 (20) 6.8 (16)
6 21.4 (18) 21.4 (19) 35.2 (81) 32.5 (76)
Unknown* — — 0.4 (1) 0.8 (2)
Dose reductions at cycle
1 12.5 (10 of 80) 3.6 (3 of 83) 3.2 (7 of 218) 1.8 (4 of 221)
2 17.6 (12 of 68) 24.6 (18 of 73) 17.6 (34 of 193) 13.4 (27 of 201)
3 16.7 (10 of 60) 13.2 (7 of 53) 17.1 (29 of 169) 11.1 (17 of 153)
4 14.9 (7 of 47) 31.1 (14 of 45) 20.3 (30 of 148) 18.0 (24 of 133)
5 16.7 (4 of 24) 20.8 (5 of 24) 15.8 (16 of 101) 12.0 (11 of 92)
6 11.1 (2 of 18) 10.5 (2 of 19) 18.5 (15 of 81) 17.1 (13 of 76)
Dose delays at cycle
1 11.2 (9 of 80) 7.2 (6 of 83) 5.5 (12 of 218) 4.1 (9 of 221)
2 27.9 (19 of 68) 23.3 (17 of 73) 27.5 (53 of 193) 16.9 (34 of 201)
3 31.7 (19 of 60) 20.8 (11 of 53) 21.9 (37 of 169) 15.0 (23 of 153)
4 34.0 (16 of 47) 20.0 (9 of 45) 23.0 (34 of 148) 12.8 (17 of 133)
5 16.7 (4 of 24) 8.3 (2 of 24) 23.8 (24 of 101) 10.9 (10 of 92)
6 33.3 (6 of 18) 21.0 (4 of 19) 27.2 (22 of 81) 14.5 (11 of 76)
Day 8 gemcitabine not administered
1 16 9
2 3 11
3 4 5
4 5 8
5 3 2
6 1 1
NOTE. Data are given as % (No.).
*Patients known to have started chemotherapy, but number of cycles are unknown (data not received from site).
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Table A4. Reasons Why Patients Did Not Start Chemotherapy After Random Assignment or Why Others Stopped Before Six Cycles (after starting chemotherapy)
Squamous Histology Nonsquamous Histology
Cisplatin and
Gemcitabine
Paclitaxel and
Gemcitabine
Cisplatin and
Pemetrexed
Paclitaxel and
Pemetrexed
Did not start chemotherapy at all, No.
Total 4 6 11 11
Adverse event 1 3 2
Clinical decision/patient unﬁt 1 2 5 3
Died 2 1 1 2
Disease progression 2 1
Patient request 1
Had palliative radiotherapy 1
Urgent safety measure* 1
Reason not reported 1 2
Started chemotherapy but stopped before six cycles,
% (No.)
Total 62 64 137† 145†
Adverse event 19.4 (12) 21.9 (14) 24.8 (34) 17.9 (26)
Clinical decision/patient unﬁt 32.3 (20) 26.6 (17) 24.1 (33) 31.7 (46)
Died 3.2 (2) 12.5 (8) 6.6 (9) 6.2 (9)
Disease progression 12.9 (8) 21.9 (14) 20.4 (28) 30.0 (43)
Intercurrent disease 1.6 (1) — 0.7 (1) 0.7 (1)
Only four cycles were intended 1.5 (2) 0.7 (1)
Patient request 9.7 (6) 6.2 (4) 8.0 (11) 4.8 (7)
Secondary malignancy 0.7 (1) 0.7 (1)
Treatment suspended . 42 days 1.6 (1) — 0.7 (1) 2.1 (3)
Urgent safety measure* 11.3 (7)‡ 9.4 (6)‡
Withdrew consent 0.7 (1) —
Reason not reported 8.1 (5) 1.6 (1) 11.7 (16) 5.5 (8)
*That is, after the statement to not use nonplatinum therapy in patients with squamous histology.
†Excluding the three patients from Appendix Table A3 who were known to have started chemotherapy, but number of cycles were not reported.
‡In the nonplatinum group, patients had stopped after one (n = 2), two (n = 2), and four (n = 2) cycles. In the platinum group, patients were recorded as having stopped
trial treatment after one (n = 2), two (n = 1), three (n = 2), and four (n = 2) cycles and were treated off-protocol.
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Table A5. Summary of Chemotherapy Doses Administered Among Patients Who Started Chemotherapy
Drug Dose According to Cycle
Squamous Histology Nonsquamous Histology
Cisplatin and Gemcitabine Paclitaxel and Gemcitabine Cisplatin and Pemetrexed Paclitaxel and Pemetrexed
Pemetrexed
1 500 (400, 950) 500 (375, 900)
2 500 (250, 950) 500 (50, 700)
3 500 (250, 930) 500 (250, 850)
4 500 (355, 930) 500 (250, 850)
5 500 (355, 930) 500 (300, 810)
6 500 (350, 930) 500 (300, 640)
Gemcitabine (day 1)
1 1,250 (1,000, 2,600) 1,250 (938, 2,356)
2 1,250 (935, 2,500) 1,250 (940, 2,300)
3 1,250 (935, 2,500) 1,250 (938, 2,300)
4 1,250 (937, 2,500) 1,250 (938, 2,300)
5 1,250 (933, 2,166) 1,250 (1,226, 1,292)
6 1,250 (933, 1,250) 1,250 (1,250, 1,292)
Cisplatin
1 75 (50, 160) 75 (56, 170)
2 75 (50, 150) 75 (53, 170)
3 75 (48, 150) 75 (53, 155)
4 75 (41, 150) 75 (38, 140)
5 75 (48, 125) 75 (38, 140)
6 75 (48, 75) 75 (38, 140)
Paclitaxel
1 175 (173, 350) 175 (131, 342)
2 175 (130, 350) 175 (88, 342)
3 175 (131, 350) 175 (88, 342)
4 175 (130, 350) 175 (88, 342)
5 175 (130, 200) 175 (106, 280)
6 175 (130, 175) 175 (105, 258)
NOTE. Data are given as median (minimum, maximum). Drug doses are mg/m2.
Table A6. Additional Treatments Administered After Trial Chemotherapy Stopped
Squamous Histology Nonsquamous Histology*
Cisplatin and
Gemcitabine
(n = 84)
Paclitaxel and
Gemcitabine
(n = 89)
Cisplatin and
Pemetrexed
(n = 230)
Paclitaxel and
Pemetrexed
(n = 234)
Any further chemotherapy 16 (19%) 15 (17%) 35 (15%) 58 (25%)
Platinum (with or without others, but not docetaxel†) 7 11 8 42
Docetaxel† (with or without others, not platinum) 5 1 16 4
Platinum and docetaxel† 2 3 4 4
Pemetrexed maintenance only 4 4
Other 2 3 4
Biologic agents 8 (10%) 11 (12%) 53 (23%) 59 (25%)
Erlotinib 8 11 50 55
Crizotinib 2
Erlotinib and crizotinib 1
Erlotinib and trial drug 1
Afatinib and erlotinib 1
Other (eg, trial drugs) 1 1
Radiotherapy 32 (38%) 43 (48%) 73 (32%) 72 (31%)
Surgery 1 4 2 4
*Appendix Table A10 presents an analysis in which the following are excluded when examining the association between ERCC1 and treatment and the effect on overall
survival and progression-free survival: 16 + four patients randomly assigned to and started cisplatin and pemetrexed who had any docetaxel therapy later on, and 42 +
four patients randomly assigned to and started paclitaxel and pemetrexed who had any platinum therapy later.
†Or any other taxane.
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Table A7. Best Tumor Response Up to the End of Chemotherapy Cycle Six
Squamous Histology Nonsquamous Histology
Cisplatin and Gemcitabine Paclitaxel and Gemcitabine Cisplatin and Pemetrexed Paclitaxel and Pemetrexed
ERCC1 positive
Total 65 68 125 128
Progressive disease 7 6 8 15
Stable disease 17 31 39 52
Partial response 24 14 43 32
Complete response 0 0 1 1
Not evaluable 2 1 0 1
Not assessed 15 16 34 27
Partial response/complete response rate* 36.9% 20.6% 35.2% 25.8%
P = .05 P = .13
Partial response/complete response rate† 50.0% 27.4% 48.4% 33.0%
P = .02 P = .04
ERCC1 negative
Total 19 21 105 106
Progressive disease 0 2 8 16
Stable disease 6 11 45 34
Partial response 8 4 25 32
Complete response 0 0 1 0
Not evaluable 2 0 3 2
Not assessed 3 4 23 22
Partial response/complete response rate* 42.1% 19.0% 24.8% 30.2%
P = .17 P = .44
Partial response/complete response rate† 57.1% 23.5% 32.9% 39.0%
P = .08 P = .51
All patients
Total 84 89 230 234
Progressive disease 7 8 16 31
Stable disease 23 42 84 86
Partial response 32 18 68 64
Complete response 0 0 2 1
Not evaluable 4 1 3 3
Not assessed 18 20 57 49
Partial response/complete response rate* 38.1% 20.2% 30.4% 27.8%
P = .01 P = .54
Partial response/complete response rate† 51.6% 26.5% 41.2% 35.7%
P = .004 P = .32
NOTE. P values from Fisher’s exact test.
Abbreviation: ERCC1, excision repair cross complementing group 1.
*As a percentage of all randomly assigned patients
†As a percentage of patients with evaluable disease (ie, progressive disease, stable disease, partial response, or complete response).
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Table A8. Odds Ratios for ERCC1 Status as a Predictive Marker of Response According to Histology (for those with progressive disease, stable disease, partial
response [PR], or complete response [CR])
OR of Having PR/CR (95% CI) for Nonplatinum v
Platinum Therapy P Interaction P*
Nonsquamous patients
ERCC1 negative 1.30 (0.68 to 2.49) .42 .04†
ERCC1 positive 0.53 (0.29 to 0.94) .03†
Squamous patients
ERCC1 negative 0.23 (0.05 to 1.08) .06 .58
ERCC1 positive 0.38 (0.16 to 0.87) .02
NOTE. Interaction P values using all patients (where not evaluable/assessed are counted as ‘not PR/CR’) were P = .70 (squamous) and P = .08 (nonsquamous).
Abbreviations: ERCC1, excision repair cross complementing group 1; OR, odds ratio.
*Interaction P values between ERCC1 status and treatment group (from a logistic regression with PR/CR as the event of interest).
†Although of borderline statistical signiﬁcance, patients on nonplatinum treatment were less likely (odds ratio 0.53) to have a PR/CR, than those on platinum therapy, but
the trial hypothesis was the opposite to this.
Table A9. Baseline Characteristics According to ERCC1 Status (8F1 antibody)
ERCC1 Status
Nonsquamous Squamous Both Combined
Negative (n = 211) Positive (n = 253) P Negative (n = 40) Positive (n = 133) P Negative (n = 251) Positive (n = 386) P
Age, years, median 64 64 .89 68 66 .13 65 65 .94
Sex, %
Male 55.5 58.1 .57 80.0 72.9 .37 59.4 63.2 .33
Female 44.5 41.9 20.0 27.1 40.6 36.8
ECOG PS, %
0 43.6 45.8 .63 45.0 36.8 .35 43.8 42.7 .79
1 56.4 54.2 55.0 63.2 56.2 57.3
Stage, %
IIIb 18.5 21.7 .38 20.0 34.6 .08 18.7 26.2 .03
IV 81.5 78.3 80.0 65.4 81.3 73.8
Smoking, %
Never 10.0 9.5 .50 2.5 4.5 .10 8.8 7.8 .90
Former 39.3 44.7 57.5 38.4 42.2 42.5
Current 50.7 45.8 40.0 57.1 49.0 49.7
Histology, %
Squamous 15.9 34.5 , .001
Nonsquamous 84.1 65.5
NOTE. P values: Wilcoxon for age, x2 for all others.
Abbreviations: ECOG, Eastern Cooperative Oncology Group; ERCC1, excision repair cross complementing group 1; PS, performance status.
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Table A10. OS and PFS HRs
OS PFS
HR (95% CI) HR (95% CI)
Nonsquamous
All patients (as in Fig 3)
ERCC1 negative 0.99 (0.73 to 1.33) 1.14 (0.86 to 1.51)
ERCC1 positive 1.11 (0.85 to 1.46) 1.18 (0.92 to 1.53)
After excluding patients who did not start trial therapy
ERCC1 negative 0.99 (0.73 to 1.35) 1.16 (0.86 to 1.56)
ERCC1 positive 1.11 (0.85 to 1.46) 1.20 (0.92 to 1.56)
Excluding patients who had certain additional treatments*
ERCC1 negative 1.16 (0.82 to 1.58) 1.29 (0.94 to 1.76)
ERCC1 positive 1.21 (0.91 to 1.61) 1.14 (0.86 to 1.50)
Squamous
All patients (as in Appendix Fig A2)
ERCC1 negative 1.64 (0.85 to 3.18) 2.94 (1.46 to 5.90)
ERCC1 positive 1.37 (0.96 to 1.95) 1.48 (1.04 to 2.11)
After patients who did not start trial therapy and censoring
the four who switched
ERCC1 negative 1.69 (0.86 to 3.35) 3.15 (1.54 to 6.45)
ERCC1 positive 1.42 (0.98 to 2.05) 1.50 (1.03 to 2.17)
NOTE. OS and PFS HRs before and after excluding the 32 patients who did not start any trial treatment (Appendix Table A4) and censoring the four patients with
squamous histology who switched from nonplatinum to platinum therapy at the date of the urgent safety measure. The table also shows the results after excluding
nonsquamous patients randomly assigned to platinum therapy only who later had a taxane, and vice versa. HRs are for nonplatinum versus platinum therapy.
Abbreviations: ERCC1, excision repair cross complementing group 1; HR, hazard ratio; OS, overall survival; PFS, progression-free survival.
*Appendix Table A6: The following patients were excluded (acknowledging this will not be based on a full randomized comparison): Patients randomly assigned to and
started cisplatin and pemetrexed who had any docetaxel (taxane) therapy later. Patients randomly assigned to and started paclitaxel and pemetrexed who had any
platinum therapy later on.
Table A11. Baseline Characteristics According to XPF Status
XPF Status
Nonsquamous Squamous Both Combined
Negative (n = 98) Positive (n = 234) P Negative (n = 45) Positive (n = 98) P Negative (n = 143) Positive (n = 332) P
Age, years, median 63 65 .47 66 63 .38 64 65 .32
Sex, %
Male 54.1 57.3 .59 77.8 72.4 .50 61.5 61.8 .96
Female 45.9 42.7 22.2 27.6 38.5 38.2
ECOG PS, %
0 39.8 43.6 .52 44.4 35.7 .32 41.3 41.3 .99
1 60.2 56.4 55.6 64.3 58.7 58.7
Stage, %
IIIb 18.4 23.5 .30 24.4 32.6 .32 20.3 26.2 .17
IV 81.6 76.5 75.6 67.4 79.7 73.8
Smoking, %
Never 8.2 9.8 .79 2.2 5.1 .65 6.3 8.4 .57
Former 42.9 44.9 40.0 42.9 42.0 44.3
Current 49.0 45.3 57.8 52.0 51.8 47.3
Histology, %
Squamous 31.5 29.5 .67
Nonsquamous 68.5 70.5
Abbreviations: ECOG, Eastern Cooperative Oncology Group; PS, performance status.
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Table A12. Using Higher Scores for XPF to Categorize Patients as Positive Among Those with Nonsquamous Histology
Deﬁnition of Positive* OS HR (95% CI) for Nonplatinum v Platinum Therapy P for Interaction Between XPF Status and Treatment
Total score $ 6 (as in Fig 4)
Positive (n = 234; rate 70%) 1.09 (0.83 to 1.44) .35
Negative (n = 98) 1.39 (0.90 to 2.15)
Total score $ 7 1.05 (0.71 to 1.41) .35
Positive (n = 204; rate 61%) 1.46 (1.00 to 2.13)
Negative (n = 128)
Total score $ 8
Positive (n = 149; rate 45%) 1.04 (0.74 to 1.47) .36
Negative (n = 183) 1.34 (0.97 to 1.83)
*On the basis of the percentage of cells stained and level of intensity.
Table A13. Subgroup Analyses of the Predictive Effects of ERCC1 or XPF
Overall Survival Progression-Free Survival
Marker Negative Marker Positive Interaction P Marker Negative Marker Positive Interaction P
Nonsquamous patients
ERCC1
Female 0.73 (0.46 to 1.17) 0.88 (0.58 to 1.33) .70 0.87 (0.56 to 1.35) 0.98 (0.65 to 1.46) .64
Male 1.22 (0.82 to 1.80) 1.35 (0.96 to 1.90) .69 1.38 (0.95 to 2.02) 1.36 (0.96 to 1.91) .90
Stage IIIb 1.20 (0.58 to 2.46) 1.62 (0.90 to 2.90) .55 1.72 (0.86 to 3.45) 1.70 (0.96 to 3.00) .83
Stage IV 0.94 (0.67 to 1.30) 1.01 (0.75 to 1.36) .82 1.05 (0.77 to 1.44) 1.10 (0.82 to 1.46) .83
Nonsmoker 0.98 (0.64 to 1.50) 1.09 (0.76 to 1.56) .79 0.97 (0.65 to 1.46) 1.23 (0.86 to 1.75) .40
Smoker 0.96 (0.62 to 1.48) 1.13 (0.77 to 1.67) .59 1.37 (0.91 to 2.05) 1.15 (0.79 to 1.67) .49
XPF
Female 0.79 (0.39 to 1.61) 1.08 (0.70 to 1.68) .42 0.95 (0.47 to 1.92) 1.06 (0.70 to 1.60) .69
Male 2.01 (1.07 to 3.77) 1.15 (0.80 to 1.65) .12 2.00 (1.10 to 3.63) 1.27 (0.89 to 1.81) .16
Stage IIIb 0.88 (0.32 to 2.46) 1.89 (1.03 to 3.46) .17 1.73 (0.62 to 4.87) 1.50 (0.85 to 2.63) .98
Stage IV 1.64 (0.99 to 2.69) 0.95 (0.69 to 1.30) .06 1.44 (0.89 to 2.35) 1.10 (0.81 to 1.49) .30
Nonsmoker 1.40 (0.76 to 2.58) 1.03 (0.70 to 1.50) .35 1.52 (0.82 to 2.80) 1.05 (0.73 to 1.51) .25
Smoker 1.47 (0.78 to 2.77) 1.20 (0.80 to 1.81) .67 1.43 (0.76 to 2.69) 1.41 (0.95 to 2.09) .98
Squamous patients
ERCC1
Nonsmoker 1.44 (0.63 to 3.29) 1.68 (0.97 to 2.92) .78 2.20 (0.95 to 5.10) 2.18 (1.26 to 3.79) .98
Smoker 1.92 (0.63 to 5.81) 1.17 (0.73 to 1.87) .24 4.44 (1.10 to 17.89) 1.09 (0.68 to 1.74) .03
XPF
Nonsmoker 1.18 (0.45 to 3.10) 1.67 (0.92 to 3.04) .68 1.37 (0.52 to 3.63) 2.31 (1.27 to 4.20) .35
Smoker 0.90 (0.40 to 2.01) 1.58 (0.84 to 2.97) .20 1.45 (0.64 to 3.28) 1.57 (0.84 to 2.95) .45
NOTE. In relation to sex, disease stage, and smoking. Data are given as hazard ratios and 95% CIs for nonplatinum versus platinum therapy, among patients with
nonsquamous histology, and smoking status for squamous histology (because of potential correlation with ERCC1). Nonsmoker is deﬁned as never smoker plus former
smokers. There are only two interaction P values, .05, but only P = .03 (weak evidence for interaction), possibly as a result of chance, given themultiple analyses above.
Abbreviation: ERCC1, excision repair cross complementing group 1.
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Table A14. Grade 3 to 5 Adverse Events, Treatment or Disease Related
Squamous Histology Nonsquamous Histology
Cisplatin and Gemcitabine
(n = 84)
Paclitaxel and Gemcitabine
(n = 89)
Cisplatin and Pemetrexed
(n = 230)
Paclitaxel and Pemetrexed
(n = 234)
Any grade 3-5 event 66.7 70.8 69.1 72.2
Events that led to death* 3 5 12 (10)† 8
Any grade 3-4 event 84.3 87.4 66.1 70.9
Grade 3 and 4 events
Low lymphocytes 2.4 0 0.43 0.85
Low neutrophils‡ 15.5 10.1 12.2 15.4
Low platelets‡ 9.5 5.6 2.2 1.7
Low red blood cells‡ 10.7 3.4 4.8 6.4
Low white cells‡ 9.5 3.4 2.6 6.0
Any hematologic event 23.8 14.6 15.6 21.4
Clinical symptoms
Acute kidney injury‡ 0 1.1 0.43 0
Alopecia‡ 1.2 2.2 0.43 3.8
Anaphylaxis 0 1.1 0.43 0.85
Appetite (low) 2.4 6.7 2.6 2.6
Chest pain 1.2 2.2 3.5 4.7
Confusion 0 0 0.87 1.7
Constipation‡ 3.6 2.2 0.87 0.85
Cough 1.2 1.1 0.87 0.43
Diarrhea‡ 0 4.5 3.9 4.7
Dysphagia 3.6 1.1 0.43 0.43
Dyspnea 7.1 11.2 11.7 12.4
Fatigue‡ 16.7 16.9 16.1 20.5
Fever‡ 0 1.1 1.3 1.7
Fracture 0 0 0.87 1.7
GI (other) 0 0 1.3 0.43
Headache 2.4 0 1.3 1.3
Hearing problems‡ 0 1.1 1.3 0.43
Heart problems 3.6 4.5 3.0 4.3
Hypertension 1.2 0 0.43 0.43
Infection‡ 16.7 19.1 16.1 19.7
Insomnia 0 0 1.3 0.85
Mucositis (oral)‡ 1.2 3.4 2.2 1.7
Nausea‡ 4.8 3.4 9.6 3.4
Neuropathy 1.2 7.9 1.3 4.7
Pain 10.7 19.1 7.4 14.1
Peripheral ischemia 1.2 0 0.87 0
Pruritis/itching‡ 0 0 0.43 0
Pulmonary embolism 3.6 2.2 6.1 6.8
Rash‡ 1.2 0 0.43 1.7
Sepsis 0 2.2 0.43 1.7
Stroke 1.2 0 1.3 0.43
Thrombotic event 3.6 2.2 3.0 4.3
Vomiting‡ 2.4 2.2 8.7 4.3
Other 28.6 16.8 16.1 15.0
Any clinical 3 to 4 event 60.7 67.4 63.5 64.5
Laboratory adverse events
Raised ALT‡ 0 1.1 0.87 5.1
Raised AST‡ 0 1.1 0 0.43
Raised ALP 0 0 1.3 1.3
Raised GGT 1.2 3.4 0.87 3.0
Hypoalbuminemia 0 2.2 0.43 1.7
Hyponatremia 2.4 3.4 2.6 2.1
NOTE. Data are given as percentages of the total number; where there were ﬁve or more occurrences. The differences between the proportions that had any
hematologic event were not statistically signiﬁcant: 23.8% versus 14.6% (squamous patients, P = .12), and 15.6% versus 21.4% (nonsquamous patients, P = .11). The
event rate was slightly higher in the nonplatinum groups for pain (14.1% v 7.4% nonsquamous; 19.1% v 10.7% squamous).
Abbreviations: ALP, alkaline phosphatase; GGT, g-glutamyl transferase.
*Appendix Table A15 lists details.
†Patients (n = 2) did not start trial treatments, so effectively, there were n = 10 patients.
‡Toxicity was prespeciﬁed as being of interest.
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Table A15. Details of Serious Adverse Events That Were Associated With Death
Squamous Histology Nonsquamous Histology
Cisplatin and Gemcitabine
Paclitaxel and
Gemcitabine
Cisplatin and
Pemetrexed
Paclitaxel and
Pemetrexed
No. 3 5 12 (10)* 8
Cause 2 hemorrhage (pulmonary; lower GI) 2 lung infection† 4 myocardial
infarction‡
1 myocardial infarction
1 collapsed (lung cancer later stated as cause of
death)
1 dysphagia 4 lung infection*§ 2 lung infection†
1 cardiac failure 1 stroke 1 pneumonitis†
1 not reported 1 neutropenic sepsisk 1 pneumothorax
1 respiratory failure* 1 neutropenia¶
1 not reported† 1 perforated bowel†
1 not speciﬁed#
Considered at least possibly treatment
related
1 6 5
NOTE. See Appendix Table A14. Serious adverse events were either disease or treatment related.
*n = 1 patient with lung infection and another with respiratory failure did not start any trial chemotherapy; therefore, n = 10 serious adverse events as a result of death
among patients who started chemotherapy.
†n = 1 considered possibly treatment related.
‡n = 1 considered possibly treatment related; and n=1 probably treatment-related.
§n = 2 considered possibly treatment related.
kConsidered deﬁnitely treatment related.
¶Considered probably treatment related.
#n = 1 considered probably treatment related but lung cancer later stated as cause of death.
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Table A16. Quality of Life (EORTC QLQ-C30 and the lung cancer module LC13, version 3.0)
Item
Nonsquamous Squamous
Baseline Mean:
Paclitaxel and
Pemetrexed
Baseline Mean:
Cisplatin and
Pemetrexed
Mean Difference
During and After
Treatment, 99% CI
Baseline Mean:
Paclitaxel and
Gemcitabine
Baseline Mean:
Cisplatin and
Gemcitabine
Mean Difference
During and After
Treatment, 99% CI
Global health status 62.3 63.0 0.8 (23.6 to 5.3) 59.0 62.1 24.2 (210.4 to 2.0)
Functional scales
Physical 76.8 75.3 0.4 (24.4 to 5.2) 67.8 75.9 28.7 (215.9 to 21.5)
Role 67.4 68.7 20.9 (27.5 to 5.6) 59.5 68.4 28.0 (218.3 to 2.4)
Emotional 74.0 74.3 20.3 (-4.9 to 4.4) 71.0 73.0 24.4 (211.5 to 2.8)
Cognitive 83.8 85.0 1.4 (23.3 to 6.0) 79.2 86.8 22.0 (29.1 to 5.0)
Social 72.6 75.7 22.6 (28.2 to 3.1) 70.6 73.2 24.2 (213.7 to 5.4)
Symptom scales
Fatigue 37.1 34.0 1.1 (-3.9 to 6.1) 41.1 36.2 5.2 (22.8 to 13.3)
Nausea/vomiting 9.3 10.2 -4.5 (27.8 to 21.1)* 12.3 6.4 1.2 (24.1 to 6.6)
Pain 30.0 26.1 0.7 (24.8 to 6.2) 36.6 25.4 7.1 (21.8 to 16.1)
Dyspnea 37.3 37.8 2.1 (23.9 to 8.1) 44.9 40.4 5.5 (23.5 to 14.6)
Insomnia 36.3 36.5 0.3 (25.7 to 6.3) 39.1 29.3 5.5 (24.9 to 15.8)
Appetite loss 26.6 27.0 20.4 (26.2 to 5.2) 34.1 19.5 9.0 (20.6 to 18.6)
Constipation 19.4 17.2 22.0 (26.6 to 2.6) 20.2 21.0 0.2 (28.4 to 8.8)
Diarrhea 6.9 6.3 20.9 (23.8 to 1.9) 7.8 7.9 2.2 (22.5 to 6.9)
Financial problems 19.6 21.7 20.6 (26.9 to 5.7) 21.8 22.8 21.4 (211.0 to 8.2)
LC13 symptoms
Dyspnea 27.4 29.0 0.5 (24.6 to 5.6) 32.4 29.2 5.7 (22.7 to 14.1)
Coughing 43.3 47.1 22.6 (27.7 to 2.5) 48.1 42.2 4.8 (23.0 to 12.5)
Hemoptysis 3.0 3.4 20.2 (21.8 to 1.4) 7.4 7.5 0.4 (24.1 to 4.9)
Sore mouth 5.8 7.1 22.7 (26.4 to 0.9) 10.3 6.2 2.8 (22.9 to 8.5)
Dysphagia 5.2 5.8 21.2 (24.4 to 1.9) 8.6 4.0 4.3 (21.4 to 10.0)
Peripheral neuropathy 4.0 6.1 8.3 (4.2 to 12.4)* 11.1 8.9 12.7 (4.2 to 21.2)*
Alopecia 2.8 2.3 31.5 (27.3 to 35.7)* 2.9 2.2 27.4 (20.5 to 34.4)*
Pain in chest 19.5 18.1 21.5 (25.8 to 2.8) 23.3 19.5 1.0 (25.7 to 7.7)
Pain arm/shoulder 21.7 17.3 0.5 (24.3 to 5.2) 28.0 22.1 6.4 (22.0 to 14.8)
Pain in other parts 23.1 22.9 4.0 (21.3 to 9.3) 22.4 19.1 1.1 (27.8 to 10.0)
Help from pain medication† 63.8 63.6 20.2 (25.7 to 5.3) 63.5 61.8 4.1 (23.7 to 11.9)
Scores range from 0 to 100 for each item. For the global health and functional scales, 0 indicates poor health and 100 good health. For all other scales, 0 indicates no
symptoms and 100 high level of symptoms. The mean difference is the treatment effect for nonplatinum minus platinum, from a repeated measures mixed model,
allowing for the baseline values. For the global health and functional scales, a positive mean difference indicates that nonplatinum was better and a negative difference
indicates that platinumwas better. For all other scales, a negativemean difference indicates that nonplatinumwas better and a positive difference indicates that platinum
was better. 99% CIs are shown because there are multiple analyses. As expected, paclitaxel and pemetrexed was associated with fewer patients with nausea and
vomiting in nonsquamous patients (P = .001). Platinum therapy caused less peripheral neuropathy and alopecia in both squamous and nonsquamous patients (P, .001
for both).
*Associations that had P values # .001.
†For those who took pain medication.
Table A17. Comparison of the Median OS and PFS in Squamous Histology Patients Between the ERCC1 Trial and Other Studies
Median, Months
ERCC1 Trial Lee et al, 200922 Scagliotti, 200823 UK National Audit Data, (LUCADA)
Cisplatin and
Gemcitabine
(n = 84)
Paclitaxel and
Gemcitabine
(n = 89)
Carboplatin and
Gemcitabine
(n = 239)
Cisplatin and
Gemcitabine
(n = 229) Platinum Therapy
OS 11.4 8.7 9.4 10.8 ~9
PFS 8.4 6.0 5.8 5.5
Abbreviations: OS, overall survival; PFS, progression-free survival.
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